Chronic Pruritus Market Set for Significant Expansion by 2034, Predicts DelveInsight
DelveInsight's 'Chronic Pruritus - Market Insight, Epidemiology, And Market Forecast - 2034″ report offers an in-depth understanding of the Chronic Pruritus, historical and forecasted epidemiology as well as the Chronic Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Some of the key facts of the Chronic Pruritus Market Report:
• According to DelveInsight, the market for Chronic Pruritus in the 7MM is expected to witness notable growth during the study period from 2020 to 2034.
• The 12-month cumulative incidence of chronic pruritus in the general population may be as high as ~7%.
• KORSUVA (difelikefalin) is the first FDA-approved treatment for Chronic Kidney Disease-Associated Pruritus (CKD-aP).
• Other treatments for chronic pruritus include topical and systemic corticosteroids, antihistamines, immunomodulators, phototherapy, and other off-label medications.
• In Dec 2024, Galderma received U.S. FDA approval for Nemluvio® (Nemolizumab) for patients with moderate-to-severe atopic dermatitis.
• In Aug 2024, Galderma received U.S. FDA approval for Nemluvio® (Nemolizumab) for adult patients living with prurigo nodularis.
• In May 2024, Clexio reached the 50% enrollment milestone in the CLE-400 Phase II proof-of-concept study for subjects suffering from chronic pruritus associated with Notalgia Paresthetica.
• Emerging drugs in the chronic pruritus pipeline include Dupixent, CLE-400, and others.
• Key players in the chronic pruritus market include Sanofi, Keymed Biosciences, Bellus Health, Clexio Biosciences, and others.
To Know in detail about the Chronic Pruritus market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Chronic Pruritus Market Forecast
Chronic Pruritus Overview
Chronic pruritus (persistent itching) is a distressing condition lasting for more than six weeks, often associated with dermatological, neurological, systemic, or psychogenic disorders. Common causes include eczema, psoriasis, chronic kidney disease, diabetes, and nerve disorders. The persistent itch significantly impacts quality of life, leading to sleep disturbances, anxiety, and depression. Management depends on the underlying cause and may involve antihistamines, corticosteroids, immunomodulators, or targeted biologics.
Get a Free sample for the Chronic Pruritus Market Report: https://www.delveinsight.com/report-store/chronic-pruritus-market
Chronic Pruritus Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Pruritus Epidemiology Segmentation:
The Chronic Pruritus epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Prevalence-specific cases of chronic pruritus
• Disease-specific cases of chronic pruritus
Download the report to understand which factors are driving Chronic Pruritus epidemiology trends @ Chronic Pruritus Epidemiology Forecast
Chronic Pruritus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pruritus market or expected to be launched during the study period. The analysis covers the market uptake of chronic pruritus by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Pruritus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Pruritus Market Strengths
• New insights into the neurological pathways of chronic itch are driving novel treatment developments.
• The growing recognition of chronic pruritus as a serious condition fuels demand for effective therapies.
Chronic Pruritus Market Weaknesses
• Many current treatments provide only symptomatic relief without addressing the root cause.
• Patients with refractory pruritus often struggle to find effective and long-term solutions.
Scope of the Chronic Pruritus Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Pruritus Therapies: Dupixent, CLE-400, and others.
• Key Chronic Pruritus Companies: Sanofi, Keymed Biosciences, Bellus Health, Clexio Biosciences, and others.
• Chronic Pruritus Therapeutic Assessment: Chronic Pruritus currently marketed and Chronic Pruritus emerging therapies
• Chronic Pruritus Market Dynamics: Chronic Pruritus market drivers and Chronic Pruritus market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Pruritus Unmet Needs, KOL's views, Analyst's views, Chronic Pruritus Market Access and Reimbursement
To learn more about the key players and advancements in the Chronic Pruritus Treatment Landscape, visit the Chronic Pruritus Market Analysis Report
Table of Contents
1. Chronic Pruritus Market Report Introduction
2. Executive Summary for Chronic Pruritus
3. SWOT analysis of Chronic Pruritus
4. Chronic Pruritus Patient Share (%) Overview at a Glance
5. Chronic Pruritus Market Overview at a Glance
6. Chronic Pruritus Disease Background and Overview
7. Chronic Pruritus Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Pruritus
9. Chronic Pruritus Current Treatment and Medical Practices
10. Chronic Pruritus Unmet Needs
11. Chronic Pruritus Emerging Therapies
12. Chronic Pruritus Market Outlook
13. Country-Wise Chronic Pruritus Market Analysis (2020–2034)
14. Chronic Pruritus Market Access and Reimbursement of Therapies
15. Chronic Pruritus Market Drivers
16. Chronic Pruritus Market Barriers
17. Chronic Pruritus Appendix
18. Chronic Pruritus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name:DelveInsight
Contact Person: Jatin Vimal
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website:https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Chronic Pruritus Market Set for Significant Expansion by 2034, Predicts DelveInsight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
5 hours ago
- Cision Canada
Triojection® from SpinaFX Granted Breakthrough Device Designation by U.S. FDA for Minimally Invasive Lumbar Disc Treatment
TORONTO, Aug. 15, 2025 /CNW/ - SpinaFX Medical Inc., ("SpinaFX") a leading innovator in image-guided interventional spine care, is proud to announce that its flagship device, Triojection®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This milestone acknowledges Triojection's potential to offer a highly effective, more accessible, and safer treatment for patients suffering from contained lumbar disc herniations, a condition recognized as one of the most common causes of disability worldwide. The Breakthrough Devices Program is designed to expedite the development and review of medical devices that demonstrate clear advantages over existing technologies for serious or life-threatening conditions. This designation grants SpinaFX prioritized access to the FDA, fostering a collaborative approach to regulatory processes and accelerating the path toward commercialization and clinical availability. A Technological Leap in Spine Care Triojection is a minimally invasive, image-guided procedure that leverages a proprietary oxygen-ozone delivery system to reduce pressure within the disc and alleviate nerve compression. Unlike more invasive surgical approaches or prolonged conservative treatments that may fail to provide relief, Triojection offers a targeted, outpatient solution that can be performed in a variety of healthcare settings from hospitals and ambulatory surgical centers to clinics in emerging markets. The device meets the FDA's stringent Breakthrough criteria: Providing a unique, novel and more effective treatment for patients with contained disc herniations. Representing a true technological innovation in the spinal care landscape. Demonstrating significant advantages in terms of safety, recovery time, cost, and accessibility. Showing strong potential to improve outcomes across diverse economic and geographic contexts, including under-resourced health systems. Meeting an Urgent Global Need Lumbar disc herniation affects millions of people globally and is a leading contributor to chronic pain, loss of mobility, reduced productivity, and diminished quality of life. Existing treatments often fall into two extremes: conservative care, which may not always bring relief, or invasive surgery, which carries risks, high costs, and extended recovery times. Triojection fills a critical therapeutic gap. It offers an evidence-based, low-barrier, cost-effective alternative that can be deployed rapidly and with minimal infrastructure ideal for both advanced and developing market health systems. "Our mission is to transform spine care and make meaningful minimalist solutions accessible to all," said Prof. Kieran Murphy MD, Chairman, Founder and Chief Medical Officer at SpinaFX. "This designation by the FDA validates the scientific merit of Triojection and 21 years of work by many people who have helped get us to this point. It's a vote of confidence in the future of inventiveness in spine health. We sincerely thank all our investors for their support and trust." Backed by Global Expertise and Scientific Rigor This regulatory milestone is the result of over two decades of research and development, including multiple international studies and collaborations with leading clinical experts in Italy, Switzerland, Greece, the United States and Canada. SpinaFX acknowledges the contributions of its diverse network of engineers and investigators, including Prof. Mario Muto (Italy) and Prof. Alexis Kelekis (Greece), both pioneers in the field of Interventional Neuroradiology. Clinical data supporting Triojection's efficacy continues to build, with upcoming publications expected to highlight its outcomes across multicenter trials. The company's engineering, regulatory, and clinical affairs teams along with trusted partners across Europe and the United States have played a critical role in advancing the technology toward approval and adoption. A Platform for Future Innovation Beyond this first indication, SpinaFX is exploring additional applications of its oxygen-ozone delivery platform in treating other disc-related conditions and musculoskeletal disorders. The company is also expanding its educational programs to train physicians in safe, effective, and evidence-based use of the Triojection procedure. "Our team is honored to receive this designation, but we view it as just the beginning," said Jeff Cambra, CEO of SpinaFX. "We're committed to working hand-in-hand with the FDA to bring Triojection to patients in the U.S. and beyond. Our goal is to create a new standard in spine care that's efficient, scalable, and deeply patient-centered. " About SpinaFX SpinaFX Medical Inc. is a Canadian-based medical technology company specializing in minimally invasive, image-guided therapies for spinal disorders. Its proprietary technology platform offers non-surgical solutions for treating disc-related conditions, using a unique approach to oxygen-ozone therapy. Committed to democratizing access to advanced spine care, SpinaFX collaborates with leading academic institutions, clinicians, and healthcare providers across the globe. Forward-Looking Statement This news release contains predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance, referred to herein as "forward-looking statements", which are made as of the date of this news release or as of the effective date of information described in this release, as applicable. The forward-looking statements address anticipated events or occurrences which may include economic factors, industry trends, market demand, and corporate performance and profitability, that may have an impact on SpinaFX's success. Forward-looking statements are often identified through words or expressions including "expects", "anticipates", "plans", "projects", "estimates", "envisages", "assumes", "intends", "strategy", "goals", "objectives" or variations thereof or stating that certain actions, events or results "may", "can", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions. All forward-looking statements are based on current beliefs as well as various assumptions made by, and information currently available to SpinaFX's management team. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections, and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. We caution any person reviewing this news release not to place undue reliance on these forward-looking statements as several important factors could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. Neither SpinaFX nor its representatives undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by SpinaFX or its representatives or on behalf of either of them, except as may be required by law.
Cision Canada
a day ago
- Cision Canada
U.S. Military Study Identifies TITAN CSR® Retractor as Top Surgical Retractor for Deployed Trauma Care
Department of Defense–funded evaluation at MHSRS 2025 finds TITAN CSR® retractor delivers the greatest abdominal exposure, fastest setup, and highest overall surgeon satisfaction among systems tested. SAN ANTONIO, Aug. 14, 2025 /CNW/ -- Advanced Surgical Retractor Systems, Inc. (ASR Systems) announced today that its flagship product, the TITAN CSR® retractor, distributed by Keir Surgical in Canada, was identified as the top-performing retractor system in a Department of Defense–funded study evaluating surgical retraction platforms for forward-deployed surgical teams.
Toronto Star
a day ago
- Toronto Star
Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
Exton, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) — Lungpacer Medical Inc., a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-on Payment (NTAP) status for the AeroPace® System under the Fiscal Year 2026 Inpatient Prospective Payment System (IPPS) Final Rule, effective October 1, 2025. The AeroPace® System is an FDA-designated breakthrough device that uses periodic neurostimulation to exercise the diaphragm, helping mechanically ventilated patients to breathe independently faster. Clinical evidence shows that patients treated with the AeroPace System strengthened their diaphragm by 50%, reduced their risk of being on the ventilator for 30 days by 35%, and reduced ventilator time by 3 days when compared to standard of care.
